CD8A and cancer: Several mechanisms have been proposed to explain this OS benefit, including remodeling of abnormal tumor vasculature [36], induction of mesenchymal-epithelial transition in cancer cells [37], and facilitation of CD8+ T cell proliferation [38], highlighting the multifaceted effects of eribulin on various cell types.